Nyxoah SA

Nyxoah's capital structure is characterized by a low debt-to-equity ratio of 0.15, indicating a conservative leverage profile. The company maintains a strong liquidity position with a current ratio of 3.94, supported by EUR 14.15 million in cash and equivalents. However, the company's operating cash flow is negative at EUR -12.28 million, reflecting ongoing operational losses. Profitability metrics show significant underperformance relative to industry norms. The company reported a return on equity (ROE) of -13.65% and a return on assets (ROA) of -10.53%, both of which are well below the typical thresholds for sustainable performance in the medical equipment sector. Gross profit of EUR 766,000 on revenue of EUR 1.22 million suggests margin compression, likely due to high R&D and commercialization costs. Geographically, Nyxoah's revenue is concentrated in a few key markets, with no detailed breakdown provided in the latest financials. The company's exposure to geographic concentration remains a potential risk, as it may be vulnerable to regulatory or economic shifts in its primary markets. The company's growth trajectory is mixed. While revenue of EUR 1.22 million represents a positive sign, the operating loss of EUR -12.21 million and net loss of EUR -11.91 million indicate that the company is not yet achieving profitability. Analysts have assigned a mean price target of EUR 8.62, with a median of EUR 9.00, suggesting cautious optimism about future performance. Risk factors include the company's negative operating cash flow and lack of profitability, which could pressure liquidity in the medium term. The risk assessment indicates low dilution risk, but the company's capital expenditure of EUR -254,000 and ongoing losses suggest a need for continued capital support. No immediate dilution or liquidity flags were detected in the latest filings. Recent events include the continued development and commercialization of its ASV devices, with a focus on expanding market access. The company has not disclosed any major regulatory or legal challenges in the latest filings, but its reliance on R&D and market adoption of new technologies remains a key risk.